Credit: Garvan Institute of Medical Research
Research led by the Garvan Institute of Medical Research has for the first time mapped the unique genetic profile of the skeleton s master regulator cells, known as osteocytes.
The study published today in
Nature Communications outlines the genes that are switched on or off in osteocytes, a type of bone cell that controls how other types of cells make or break down parts of the skeleton to maintain strong and healthy bones. This new information provides a kind of genetic shortlist we can look to when diagnosing bone diseases that have a genetic component, says the study s first author Dr Scott Youlten, Research Officer in the Bone Biology Lab. Identifying this unique genetic pattern will also help us find new therapies for bone disease and better understand the impacts of current therapies on the skeleton.
Researchers find new map revealing genes that control skeleton ANI | Updated: May 05, 2021 16:10 IST
Sydney [Australia], May 5 (ANI): Research led by the Garvan Institute of Medical Research has for the first time mapped the unique genetic profile of the skeleton s master regulator cells, known as osteocytes.
The study published today in Nature Communications outlines the genes that are switched on or off in osteocytes, a type of bone cell that controls how other types of cells make or break down parts of the skeleton to maintain strong and healthy bones. This new information provides a kind of genetic shortlist we can look to when diagnosing bone diseases that have a genetic component, says the study s first author Dr Scott Youlten, Research Officer in the Bone Biology Lab. Identifying this unique genetic pattern will also help us find new therapies for bone disease and better understand the impacts of current therapies on the skeleton
Image for representational purpose only |Pic: Pixabay
Research led by the Garvan Institute of Medical Research has for the first time mapped the unique genetic profile of the skeleton s master regulator cells, known as osteocytes.
The study published today in Nature Communications outlines the genes that are switched on or off in osteocytes, a type of bone cell that controls how other types of cells make or break down parts of the skeleton to maintain strong and healthy bones. This new information provides a kind of genetic shortlist we can look to when diagnosing bone diseases that have a genetic component, says the study s first author Dr Scott Youlten, Research Officer in the Bone Biology Lab. Identifying this unique genetic pattern will also help us find new therapies for bone disease and better understand the impacts of current therapies on the skeleton.
Researchers have mapped the gene activity of osteocytes to improve their understanding of skeletal disease.
Research led by the Garvan Institute of Medical Research has for the first time mapped the unique genetic profile of the skeleton’s ‘master regulator’ cells, known as osteocytes.
The study published today in Nature Communications outlines the genes that are switched on or off in osteocytes, a type of bone cell that controls how other types of cells make or break down parts of the skeleton to maintain strong and healthy bones.
“This new information provides a kind of genetic shortlist we can look to when diagnosing bone diseases that have a genetic component,” says the study’s first author Dr Scott Youlten, Research Officer in the Bone Biology Lab. “Identifying this unique genetic pattern will also help us find new therapies for bone disease and better understand the impacts of current therapies on the skeleton.”
New Bone Cell Type Identified, Could Point to Drug Targets for Osteoporosis and Other Skeletal Diseases
February 26, 2021
Source: Photo by Mathew Schwartz on Unsplash
Researchers at the Garvan Institute of Medical Research have discovered a new type of bone cell that may yield novel therapeutic targets and strategies for osteoporosis and other skeletal diseases.
The cells, which the researchers have called osteomorphs, are found in the blood and bone marrow, and fuse together to form osteoclasts, which are specialized cells that break down bone tissue. The newly identified osteomorphs have a unique genomic profile that indicates potentially promising, and as yet unexplored targets for therapy.